ALPROLIX

sanofi-aventis canada inc🇨🇦 Health Canada

Approval Id: 85c59ac8e4174504
Drug Approval Canada Name: ALPROLIX
Product Name: ALPROLIX
Status: Marketed
Status Date: 2021-10-22
Original Market Date: 2016-01-15
Din: 02422956
Drug Class: Human
Dosage Form: Powder For Solution , Kit
Route Of Administration: Intravenous
Schedule: Schedule D
Ahfs: 20:28.16
Atc Original: B02BD04 COAGULATION FACTOR IX
Atc Name: b 02 bd 04
Aig Number: 0155510005
Company Name: sanofi-aventis canada inc
Company Address: 1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

3000 UNIT / VIAL

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

85c59ac8e4174504

Type

Standard